Published in Thromb Haemost on October 01, 2005
[Perioperative conversion of oral anticoagulants to heparin (bridging) in ophthalmic medicine]. Ophthalmologe (2010) 1.39
Bridging the gap between evidence and practice in venous thromboembolism prophylaxis: the quality improvement process. J Gen Intern Med (2007) 1.11
Venous thromboembolic disease. J Natl Compr Canc Netw (2011) 0.93
Venous thromboembolism in malignant gliomas. J Thromb Haemost (2009) 0.92
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis (2011) 0.86
Use and outcomes of venous thromboembolism prophylaxis after spinal fusion surgery. J Thromb Haemost (2011) 0.85
Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2011. Clin Res Cardiol (2011) 0.85
Thrombotic risk assessment questionary helps increase the use of thromboprophylaxis for patients with pelvic and acetabular fractures. Indian J Orthop (2012) 0.84
External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc (2014) 0.83
Determinants of venous thromboembolism among hospitalizations of US adults: a multilevel analysis. PLoS One (2015) 0.82
Is thrombophilia a major risk factor for deep vein thrombosis of the lower extremities among Lebanese patients? Vasc Health Risk Manag (2009) 0.81
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2016) 0.80
Eliminating Health Care Disparities With Mandatory Clinical Decision Support: The Venous Thromboembolism (VTE) Example. Med Care (2015) 0.79
II Italian intersociety consensus statement on antithrombotic prophylaxis in orthopaedics and traumatology: arthroscopy, traumatology, leg immobilization, minor orthopaedic procedures and spine surgery. J Orthop Traumatol (2012) 0.79
Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines. Thromb J (2008) 0.78
Correlates of in-hospital deaths among hospitalizations with pulmonary embolism: findings from the 2001-2008 National Hospital Discharge Survey. PLoS One (2012) 0.78
Primary prevention of venous thromboembolism in elderly medical patients. Clin Interv Aging (2008) 0.78
Adherence to local guidelines for venous thromboprophylaxis: a cross-sectional study of medical inpatients in Argentina. Thromb J (2011) 0.77
Antithrombotic prophylaxis in the middle East. Mediterr J Hematol Infect Dis (2011) 0.76
Value of venous color flow duplex scan as initial screening test for geriatric inpatients with clinically suspected pulmonary embolism. Vasc Health Risk Manag (2011) 0.76
An update on prevention of venous thromboembolism in hospitalized acutely ill medical patients. Thromb J (2006) 0.76
Improving venous thromboembolism risk assessment compliance using the electronic tool in admitted medical patients. BMJ Qual Improv Rep (2015) 0.75
Inflammatory bowel disease and thrombosis. Turk J Haematol (2012) 0.75
Impact of thromboprophylaxis across the US acute care setting. PLoS One (2015) 0.75
Assessing the Caprini Score for Risk Assessment of Venous Thromboembolism in Hospitalized Medical Patients. Am J Med (2015) 0.75
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet (2008) 9.10
Multidetector computed tomography for acute pulmonary embolism. N Engl J Med (2006) 7.57
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med (2008) 6.32
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med (2008) 6.00
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med (2010) 5.79
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med (2012) 5.25
Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med (2003) 5.02
Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med (2013) 4.43
Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III). Ann Intern Med (2010) 4.15
Clinical practice. The evaluation of suspected pulmonary embolism. N Engl J Med (2003) 3.90
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation (2004) 3.83
Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation (2012) 3.74
The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.74
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost (2007) 3.67
Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED II. Am J Med (2007) 3.16
Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med (2003) 2.64
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation (2013) 2.64
Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol (2009) 2.57
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol (2010) 2.55
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation (2006) 2.54
Prevention of venous thromboembolism in the orthopedic surgery patient. Cleve Clin J Med (2008) 2.51
Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology (2004) 2.38
Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med (2004) 2.34
Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med (2011) 2.32
Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation (2012) 2.16
Diagnostic pathways in acute pulmonary embolism: recommendations of the PIOPED II investigators. Am J Med (2006) 2.13
Diagnostic pathways in acute pulmonary embolism: recommendations of the PIOPED II Investigators. Radiology (2007) 2.09
Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation (2004) 2.05
Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med (2006) 2.05
Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol (2005) 1.97
The consult guys--anticoagulation? Antiplatelet? What's the score? Ann Intern Med (2015) 1.95
A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol (2004) 1.92
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med (2006) 1.86
Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm (2005) 1.81
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost (2012) 1.77
Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis (2007) 1.72
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest (2003) 1.71
A nitric oxide processing defect of red blood cells created by hypoxia: deficiency of S-nitrosohemoglobin in pulmonary hypertension. Proc Natl Acad Sci U S A (2005) 1.67
Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest (2010) 1.67
Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med (2005) 1.64
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost (2008) 1.64
End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol (2009) 1.63
Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event. Thromb Haemost (2011) 1.61
Outcome of lung transplantation in patients with mycetomas. Chest (2002) 1.59
Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol (2013) 1.55
Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res (2006) 1.48
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost (2010) 1.47
Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect. Eur J Heart Fail (2003) 1.46
Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism? Br J Haematol (2009) 1.46
Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thromb Haemost (2003) 1.43
Thrombosis prophylaxis in orthopedic surgery: current clinical considerations. J South Orthop Assoc (2002) 1.43
Thrombosis during pregnancy and the postpartum period. Am J Obstet Gynecol (2005) 1.42
A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions. Am Heart J (2006) 1.41
SPECT in acute pulmonary embolism. J Nucl Med (2009) 1.40
Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension. J Cardiovasc Pharmacol (2016) 1.39
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery. Clin Pharmacokinet (2008) 1.39
[Treatment trial methodology in internal medicine]. Presse Med (2007) 1.38
Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol (2003) 1.37
The Prophylaxis of Venous Thromboembolism. Dtsch Arztebl Int (2016) 1.36
Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med (2005) 1.35
Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother (2008) 1.32
Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther (2004) 1.30
The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can J Cardiol (2011) 1.25
End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol (2004) 1.24
Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost (2014) 1.22
Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. FEMS Immunol Med Microbiol (2008) 1.22
Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey. Thromb Haemost (2010) 1.21
International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J (2011) 1.20
Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci (2004) 1.20
Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost (2005) 1.19
Signal quality of single dose gadobenate dimeglumine pulmonary MRA examinations exceeds quality of MRA performed with double dose gadopentetate dimeglumine. Int J Cardiovasc Imaging (2011) 1.17
Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol (2014) 1.12
Factors in the technical quality of gadolinium enhanced magnetic resonance angiography for pulmonary embolism in PIOPED III. Int J Cardiovasc Imaging (2011) 1.11
Thrombolytic therapy for acute pulmonary embolism: a critical appraisal. Chest (2009) 1.11